Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Fresenius Medical Care FMS steht im Mittelpunkt eines Dialysemarktes, in dem Patientenzuwachs auf Kapazitäten, Arbeitskräfte und Kostenstruktur drückt. Die Modalität und Technologieentscheidungen sind nicht nur ein medizinisches Gespräch, sondern können auch den Markenanteil, die Auslastung und die Stabilität der Volumentrends beeinflussen, während sich das Unternehmen mit mehr Patienten auseinandersetzt.

Die Erwartung ist, dass die globale Dialyse-Nachfrage weiterhin bei etwa 4-5% pro Jahr wächst, mit einer Behandlungsbevölkerung von etwa 7 Millionen Menschen bis 2035. Wenn ein Markt so schnell wächst, kann sich der Grenzwert vom Bedarf zu Kapazitäten und Kosten verschieben. Deshalb sind Verschiebungen hin zu Heimdialyse und höher leistungsfähigen In-Zentren-Modalitäten wichtig. Sie beeinflussen, wo das Wachstum landet, wie effizient es bedient wird und welche Anbieter ohne Qualitätseinbußen skalieren können.

Fresenius Modalitätsschub: Heimdialyse gewinnt an Bedeutung Heimdialyse ist als struktureller Hebel positioniert, da Patientenzuwachs Druck auf Kosten und Kapazitäten ausübt. FMS unterstützt bereits mehr als 85.000 Heimpatienten weltweit über Heimhemodialyse- und Peritonealdialyseprogramme.

In den USA ist die Heimdialyse noch eine Minderheit der Behandlungen, aber sie bewegt sich höher. FMS zitiert etwa 16% der US-Dialysebehandlungen im Jahr 2025 als Heimdialyse durchgeführt, mit einer Erwartung von etwa 25% bis 2027. Wenn diese Fortschritte eintreten, ändert sich die Art und Weise, wie das Unternehmen Kapital und Personal verteilt, und es kann den Marktanteil verteidigen, indem es Patienten trifft, wohin das Wachstum fließt.

FMS-Technologieinfektion: Hochvolumen-HDF-Möglichkeit Die disruptive Katalysator ist der Schub hin zu hochvolumen Hemodiafiltration (HDF) als neues Standard der Behandlung in den USA. FMS positioniert die hochvolumen HDF als eine erhebliche Möglichkeit, aufbauend auf ihrem Erfolg in internationalen Märkten und kombiniert mit einer differenzierten Plattformstrategie.

Die zugrunde liegende Logik ist so operativ wie klinisch. Wenn die hochvolumen HDF die Behandlungsqualität und Ergebnisse verbessern kann, kann sie möglicherweise weniger Behandlungen verpassen und Patientenabflüsse verlangsamen, zwei Variablen, die sich laut Bericht auf die berichteteten Volumentrends auswirken können. In diesem Szenario ist Technologie nicht nur über Premiumpositionierung hinausgegangen. Sie stabilisiert den Grund.

Fresenius 5008X-Rollout: Frühe Skalierung und Meilensteine bis 2026 Die Firma verwendet das System 5008X als Lieferfahrzeug für die hochvolumen HDF und beschreibt die Transition als größte Infrastruktur-Übernahme in der Geschichte des Unternehmens. Das System ist bereits skaliert. Die Verwaltung hat angegeben, dass es in etwa 100 US-Kliniken verfügbar ist und im April 2026 mehr als 100.000 Behandlungen durchgeführt hat.

Die Zeit ist das Schlüsselmerkmal. Der Rollout ist kostenaufwendig zu Beginn, mit erhöhten Ausgaben für Schulung und Übergang, aber die Verwaltung erwartet, dass sich operative und klinische Vorteile später im Jahr 2026 einsetzen werden. Der größere Schritt wird als eine Geschichte ab 2027 dargestellt, wenn der umgewandelte Basis größer ist und das Ausführungsrisiko nachlässt.

FMS-Qualitäts-Fließband: Infektionsreduktion und Patientenbindung Die Strategie wird durch Qualitätsinitiativen gestützt, die darauf abzielen, bessere Ergebnisse in bessere Bindung umzuwandeln. FMS hebt breite Bemühungen hervor, Blutstrominfektionen zu reduzieren und Behandlungsverlässlichkeit zu steigern, was sich in mehreren finanziellen Vorteilen widerspiegelt, wenn weniger Komplikationen die Pflege stören.

Ein konkreter Beleg ist der Aufbau von antimikrobiellen Katheter-Lock-Lösungen. Die Verwaltung hat angegeben, dass etwa 90% der berechtigten Patienten eine solche Lösung nutzen, wobei Infektionsreduktionsinitiativen zu verbesserten Ergebnissen und einem zusätzlichen finanziellen Vorteil in 2025 beitragen.

In einem Volumensmodell kann die Reduzierung von vermeidbaren klinischen Störungen ein unterschätzt wichtiger Hebel für eine stabile Auslastung sein.

Fresenius Value-Based Care: Skalieren mit Rechnungslegungs-Rauschen Value-Based Care wird immer zentraler, da es Wachstumsrichtungen außerhalb des In-Zentren-Stuhls hinzufügt. Der Segment erzielte mehr als 2 Milliarden Euro Umsatz im Jahr 2025 und erreichte zum ersten Mal die Gleichgewichtsprofitabilität, unterstützt durch Vertragsausweitungen, Mitgliedermonatengewinn und eine breitere Anbieternetzwerk.

Die potenzielle Verwirrung ist optisch. Die Verwaltung erwartet, dass der Umsatz des Value-Based Care im Laufe von 2026 negativ wird, trotz eines höheren Ersparnisrates, da die Rechnungslegung für einen großen Vertrag geändert wird. In anderen Worten kann der berichtete Umsatz in die falsche Richtung laufen, während die zugrunde liegenden Wirtschaftsdaten intakt bleiben.

FMS Was könnte den Trend brechen: Volumina und Vergütungen Die kurzfristige Gefahr ist, dass frühzeitige Signale weiterhin laut sind. Die US-Volumentrends werden als ungleichmäßig beschrieben, unter Druck durch verpasste Behandlungen und überdurchschnittliche Mortalität, wobei schwere Wetter als Haupttreiber von verpassten Behandlungen im Frühjahr 2026 genannt wird. Im ersten Quartal 2026 betrug der gleiche Markt-Wachstum in den USA -0,4%, und die Verwaltung geht davon aus, dass es für das gesamte Jahr 2026 gleichbleiben wird.

Gleichzeitig schwinden die Vergütungsimpulse. Die Phosphatbindereinigungstransitional-Drug-Add-on-Payment-Adjustment-Erträge werden auf etwa 100 Millionen Euro im Jahr 2026 von 220 Millionen Euro im Jahr 2025 fallen, wobei der größere Einfluss im zweiten Halbjahr zu erwarten ist. Wenn man die regulatorischen und inflationären Druckfaktoren hinzurechnet, einschließlich der vom Management als Gesamteffekt auf 150 bis 200 Millionen Euro für das Jahr 2026 und Inflationsspannen von 200 bis 300 Millionen Euro, können sich die Trendlinien in der Nähe kurzfristig verwischen.

Fresenius Medical Care AG & Co. KGaA Preis- und Konsens

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Fresenius Medical Care AG & Co. KGaA hat kürzlich die globale Einführung der digitalen Plattform kinexus angekündigt, um Heimdialyseprogramme zu unterstützen und eine vernetzte, patientenorientierte Pflege zu fördern. Die Plattform integriert Fernbehandlungsüberwachung, Rezeptmanagement und operative Workflows für beide peritoneale Dialyse (PD) und Heimhemodialyse (HHD) innerhalb eines Systems.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Markt für spätstadiumchronische Nierenkrankheiten (CKD) wächst rasant, getrieben durch die steigende globale Prävalenz von Diabetes, Hypertonie und dem Alterungsprozess. Fortschritte in Dialyse-Technologien, wie portablen und hausbasierten Systemen, sowie der Integration von Telemedizin, verbessern die Patientenversorgung und -adherence. Emerging-Märkte wie Asien-Pazifik und Lateinamerika bieten erhebliche Wachstumsmöglichkeiten, trotz Herausforderungen wie hohen Kosten und begrenztem Zugang in ländlichen Gebieten.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der Liberty All-Star Equity Fund hat sein monatliches Update für den April 2026 veröffentlicht. Der Fonds ist ein Large-Cap-Core-Fonds, der drei Wertinvestoren und zwei Wachstumsinvestoren kombiniert. Die Top-20-Holdings umfassen NVIDIA Corp., Alphabet Inc. und Microsoft Corp. Die Performance des Fonds beträgt 7,89% für den Monat April und -1,61% seit Beginn des Jahres. Der NAV (Net Asset Value) des Fonds beträgt $6,48 und der Marktpreis $5,85.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Quest Diagnostics logo

Key Points

Strong Q1 results and upgraded 2026 outlook: Q1 revenue was $2.9 billion (up 9.2% YoY) and adjusted EPS was $2.50 (about +13%), leading Quest to raise its 2026 guidance to $11.78–11.90 billion in revenue and $10.63–10.83 in adjusted EPS, with cash from operations ~ $1.75 billion and capex ~ $550 million. Volume growth driven by major collaborations: Total requisitions rose 10.9% (organic +10.8%), with Fresenius Medical Care and Corewell Health accounting for roughly 7 percentage points of organic volume (Corewell ~ $250M and Fresenius ~ $80–100M expected revenue contribution), while revenue per requisition fell 1.3% overall due to mix but rose ~2.5% excluding those collaborations. Productivity, AI and advanced diagnostics momentum with near-term costs: Quest is driving productivity through its Invigorate program and AI (40% customer-service productivity gain; Quest AI Companion ~350k engagements) and saw double-digit growth in advanced diagnostics (AD‑Detect more than doubled; Haystack MRD commercial ramp underway), though Project Nova and elevated fuel costs are expected to dilute ~ $0.25 of EPS in 2026 and trim roughly $0.05–$0.07 of EPS from fuel headwinds. Interested in Quest Diagnostics Incorporated? Here are five stocks we like better.

Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests

Quest Diagnostics (NYSE:DGX) reported first-quarter 2026 results that management said reflected broad-based organic growth, improving productivity from automation and artificial intelligence, and contributions from major collaborations including Fresenius Medical Care and Corewell Health. The company also raised its full-year revenue and earnings guidance following the quarter.

First-quarter results and raised 2026 outlook

Chairman, President and CEO Jim Davis said Quest delivered “strong first quarter performance” as demand increased for clinical innovations, expansions into new clinical areas, and collaborations with healthcare and consumer health organizations. Davis said revenue grew more than 9% “almost entirely from organic revenue growth,” while adjusted diluted EPS rose about 13%.

→ $39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent Inflation

LifeMD Shares Come Back to Life on GLP-1 Business Growth

CFO Sam Samad reported consolidated revenue of $2.9 billion, up 9.2% year over year, with consolidated organic revenue up 9%.

Diagnostic Information Services revenue increased 9.4% versus the prior year, which Samad attributed to strong organic growth across physician, hospital and consumer channels. Reported operating income was $399 million, or 13.8% of revenue, compared with $346 million, or 13% of revenue, a year earlier. On an adjusted basis, operating income was $447 million, or 15.4% of revenue, compared with $406 million, or 15.3% of revenue, last year.

Story Continues

→ Could These 3 New-to-Market Quantum Computing Firms Threaten D-Wave?

Exact Sciences Serves Investors Exactly What They Wished For

Quest posted reported EPS of $2.24 compared with $1.94 a year ago; adjusted EPS was $2.50 compared with $2.21. Samad said adjusted EPS growth was driven largely by organic revenue growth, increased productivity, and lower interest expense, partially offset by wage increases and weather impacts.

Cash from operations was $278 million, down from $314 million in the prior-year period due to timing of receipts and disbursements and higher bonus payments, partially offset by higher operating income.

→ Nebius Group Is Trading Near All-Time Highs, Here's How Far It Has Come

Based on first-quarter performance, Samad said Quest raised its full-year 2026 guidance and now expects:

Revenue: $11.78 billion to $11.9 billion (6.8% to 7.8% growth) Reported EPS: $9.58 to $9.78 Adjusted EPS: $10.63 to $10.83 Cash from operations: approximately $1.75 billion Capital expenditures: approximately $550 million

Samad said the revenue guide does not include contributions from prospective M&A and that operating margin is expected to expand versus the prior year.

Volume, mix, and the impact of Corewell and Fresenius

Total volume, measured by requisitions, increased 10.9% year over year, with organic volume up 10.8%. Samad said Fresenius Medical Care and Corewell Health contributed roughly 7% to organic volume growth in the quarter; excluding those relationships, organic volume growth was 3.8%.

Revenue per requisition declined 1.3% year over year, which Samad said reflected business mix from the Corewell and Fresenius collaborations, as those relationships include a greater proportion of routine tests. Excluding that mix impact, revenue per requisition increased about 2.5%. Samad said unit price reimbursement was “relatively flat,” and that the main driver of the higher revenue per requisition excluding the two collaborations was an increase in tests per requisition.

In response to a question about expectations for the rest of the year, Samad reiterated the company’s view of continued organic utilization growth and quantified the embedded revenue contribution from the two collaborations. He said Corewell was expected to contribute about $250 million to revenue growth for the year, with Fresenius adding roughly $80 million to $100 million on top of that.

Davis also pointed to test mix benefits, highlighting growth in consumer health partnerships and advanced testing panels, as well as continued strength in Alzheimer’s-related testing. He said Quest’s Alzheimer’s testing “more than doubled year-over-year.”

Channel performance: physician, hospital, and consumer

Davis said the physician channel produced high single-digit revenue growth, driven by demand for clinical innovations, geographic expansion tied to greater health plan access, and increased enterprise account volume. He also highlighted growth in end-stage renal disease testing, describing it as a new clinical area for Quest and noting volume from dialysis clinics operated by Fresenius Medical Care, as well as independent dialysis clinics and other providers for lab and water purity testing.

In the hospital channel, Davis said revenue rose at a double-digit rate, with most of the growth coming from Quest’s collaborative lab solutions for Corewell Health. He said implementation was “proceeding smoothly” and that Quest was advancing its joint venture with plans to open a “state-of-the-art lab in Southeast Michigan next year.” Davis added that Quest’s pipeline for potential Co-Lab collaborations, as well as outreach and independent acquisitions, remained strong.

In consumer health, Davis said Quest again delivered “significant revenue growth” from both questhealth.com and consumer collaborations. He cited “robust double-digit customer repeat rates” on questhealth.com and demand for newer offerings such as the Elite Health Profile as well as autoimmune and hormone tests. He also said a meaningful part of growth came from consumers accessing Quest lab insights through apps and wearables of collaborators.

Discussing consumer partnerships, Davis said questhealth.com grew “somewhere between in the high 20s%,” while growth from partnerships and value-added resellers was even stronger. He also addressed Function Health’s acquisition of Getlabs, saying Quest viewed it as positive because it can expand access to home blood draws in areas where Quest has less patient service center coverage. Samad added that the collaboration ecosystem was broad-based, with growth coming from multiple players.

On profitability of consumer offerings, Samad said margins in these collaborations and on questhealth.com were “on par, if not slightly better than our overall enterprise average,” citing cash-pay dynamics and lower complexity from fewer denials and patient concessions.

Advanced diagnostics, AI, and operational initiatives

Davis said Quest delivered double-digit revenue growth across several advanced diagnostic areas during the quarter, including brain health, cardiometabolic and endocrine testing, and other categories. He reiterated momentum in the AD-Detect blood testing franchise for Alzheimer’s disease and described the company’s test menu and algorithmic approach, noting Quest developed a proprietary algorithm combining multiple biomarkers to establish Alzheimer’s pathology with sensitivity and specificity of 90% or greater.

In cardiometabolic and endocrine testing, Davis pointed to double-digit growth in parts of the portfolio, including Lp(a) and ApoB tests, as well as kidney, liver, and reproductive hormone testing. He noted new American Heart Association guidelines that recommend Lp(a) and ApoB testing for the first time and also recommend earlier cholesterol screening.

In oncology, Davis highlighted a research collaboration with City of Hope to study use of Quest’s Haystack MRD test in monitoring recurrence and treatment decisions in clinical trial participants across 14 U.S. sites. He also discussed an arrangement with Guardant Health related to blood collections for the Shield test, saying the partnership began during the quarter but it was “early” to comment on volumes.

Samad said Quest was making progress on Haystack’s commercial ramp and reimbursement, including submission to MolDX for technical assessment to pursue Medicare Advantage reimbursement, and noted the company had PLA codes priced at $3,900 baseline and $800 for monitoring. He said it was too early to discuss the year’s EPS phasing for Haystack and that Quest would provide updates over time.

On operations, Davis said Quest’s Invigorate program targets 3% annual cost savings and productivity improvements. He cited expanded deployment of AI and automation beyond the lab, including a 40% productivity boost among customer service agents using AI to triage and route emails. Davis also described the launch of Quest AI Companion in the myQuest app, powered by Google Gemini, saying patients engaged the tool about 350,000 times since rollout in the first quarter.

Davis also said Quest was scaling planning and design work for Project Nova, a multi-year initiative to transform order-to-cash processes and systems, with the first wave of solutions targeted for implementation in fall 2027.

Samad said Project Nova’s expected impact remained $0.25 of EPS dilution for the year, though expense cadence shifted, with more than 60% of costs now expected in the second half. He also cited elevated fuel costs as a headwind of $7 million to $10 million embedded in guidance, equating to about $0.05 to $0.07 of EPS.

Policy, reimbursement, and M&A commentary

On ACA subsidies and potential disenrollments, Davis said it was “too early to tell,” adding that Quest cannot identify every ACA-related requisition, though the company believed roughly 60% can be discretely identified and it was not seeing an impact to date. Samad said guidance still assumes a 30-basis-point revenue impact from ACA disenrollments, though the company had not seen the negative impact in the first quarter.

Regarding PAMA data collection and potential 2027 Medicare rates, Davis said Quest was prepared to submit data after May 1 and noted Medicare’s guidance that entities with more than $25,000 in Medicare revenue should submit, which he said could include more than 2,600 hospital labs. He said Quest would continue pushing for the RESULTS Act and described ongoing steps such as a CMS technical assessment and CBO scoring. Davis said it was too early to speculate on 2027 rates, but argued that broader participation in data submission could result in higher rates than reflected in prior, more limited submissions.

Davis also addressed investor concerns tied to the CMS CRUSH initiative, saying Quest did not believe it would have an impact. He said an OIG report identified 10 tests driving most of the 2024 Medicare lab spending increase, with seven being PLA codes in which Quest had “nothing,” and three being genetic or molecular-based tests where Quest’s exposure was “de minimis.”

On M&A, Davis said the “M&A funnel is good,” including health system outreach opportunities and some remaining independent labs. He said potential Medicare reimbursement changes were not affecting hospitals’ views of outreach, but argued health plans were increasingly scrutinizing the higher prices paid to some hospital labs versus independent labs and that Quest advocated for paying all labs the same for outreach work.

About Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

The article "Quest Diagnostics Q1 Earnings Call Highlights" was originally published by MarketBeat.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 112 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.

This Week’s Ratings Changes:

Upgraded: Strong to Very Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AMAT Applied Materials, Inc. A B A APA APA Corporation A C A BWXT BWX Technologies, Inc. A B A CACI CACI International Inc Class A A C A CMI Cummins Inc. A C A DINO HF Sinclair Corporation A C A EME EMCOR Group, Inc. A B A GOOG Alphabet Inc. Class C A B A HTHT H World Group Limited Sponsored ADR A B A JBL Jabil Inc. A B A LMT Lockheed Martin Corporation A B A MPC Marathon Petroleum Corporation A B A MTSI MACOM Technology Solutions Holdings, Inc. A B A NVMI Nova Ltd. A C A NVT nVent Electric plc A B A VIK Viking Holdings Ltd A B A WDS Woodside Energy Group Ltd Sponsored ADR A B A XOM Exxon Mobil Corporation A C A

Downgraded: Very Strong to Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AGI Alamos Gold Inc. B A B APH Amphenol Corporation Class A A B B BIP Brookfield Infrastructure Partners L.P. A B B CLH Clean Harbors, Inc. A C B CNP CenterPoint Energy, Inc. A C B COR Cencora, Inc. A C B DG Dollar General Corporation A B B DTM DT Midstream, Inc. A C B FNV Franco-Nevada Corporation B B B GFI Gold Fields Limited Sponsored ADR A B B IX ORIX Corporation Sponsored ADR A B B MCK McKesson Corporation A C B NTR Nutrien Ltd. A C B UTHR United Therapeutics Corporation A C B VTR Ventas, Inc. A B B

Upgraded: Neutral to Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade COP ConocoPhillips B D B CQP Cheniere Energy Partners, L.P. B B B CTRA Coterra Energy Inc. B C B DAL Delta Air Lines, Inc. B C B GMED Globus Medical Inc Class A B B B HLT Hilton Worldwide Holdings Inc. B D B IHG InterContinental Hotels Group PLC Sponsored ADR B C B LH Labcorp Holdings Inc. B C B LNG Cheniere Energy, Inc. B B B LVS Las Vegas Sands Corp. B B B MAR Marriott International, Inc. Class A B D B MRNA Moderna, Inc. B C B MS Morgan Stanley B B B NIO NIO Inc. Sponsored ADR Class A B B B NUE Nucor Corporation B C B PSTG Everpure, Inc. Class A C B B RDDT Reddit, Inc. Class A C B B TPL Texas Pacific Land Corporation B C B

Downgraded: Strong to Neutral

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AEE Ameren Corporation B C C AGNC AGNC Investment Corp. C B C ALNY Alnylam Pharmaceuticals, Inc C C C ARGX argenx SE Sponsored ADR C C C BUD Anheuser-Busch InBev SA/NV Sponsored ADR C C C COST Costco Wholesale Corporation C C C CVS CVS Health Corporation C B C ELS Equity LifeStyle Properties, Inc. C C C IRM Iron Mountain, Inc. C C C JBS JBS N.V. Class A C C C LLY Eli Lilly and Company C B C LYV Live Nation Entertainment, Inc. B D C MLM Martin Marietta Materials, Inc. B D C MSI Motorola Solutions, Inc. C C C NLY Annaly Capital Management, Inc. C B C NWG NatWest Group Plc Sponsored ADR C B C PM Philip Morris International Inc. B C C REG Regency Centers Corporation C B C RIVN Rivian Automotive, Inc. Class A B D C TKO TKO Group Holdings, Inc. Class A B D C TLN Talen Energy Corp B D C UL Unilever PLC Sponsored ADR C C C WEC WEC Energy Group Inc B C C

Upgraded: Weak to Neutral

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AEG Aegon Ltd. Sponsored ADR D C C AIZ Assurant, Inc. C C C ARM ARM Holdings PLC Sponsored ADR C C C COF Capital One Financial Corp D C C DECK Deckers Outdoor Corporation D B C DXCM DexCom, Inc. D B C ENTG Entegris, Inc. C C C FTV Fortive Corp. D C C IR Ingersoll Rand Inc. D C C ISRG Intuitive Surgical, Inc. D C C NXPI NXP Semiconductors NV D C C TFC Truist Financial Corporation C C C TU TELUS Corporation C D C WSM Williams-Sonoma, Inc. C C C

Downgraded: Neutral to Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade ADSK Autodesk, Inc. D B D AMT American Tower Corporation D C D AZO AutoZone, Inc. D D D BDX Becton, Dickinson and Company D C D BJ BJ's Wholesale Club Holdings, Inc. D C D CTAS Cintas Corporation D C D EXR Extra Space Storage Inc. D C D FMS Fresenius Medical Care AG Sponsored ADR D B D HDB HDFC Bank Limited Sponsored ADR F C D LOW Lowe's Companies, Inc. D D D MSFT Microsoft Corporation D B D PSA Public Storage D C D PTC PTC Inc. D B D RBLX Roblox Corp. Class A D C D RDY Dr. Reddy's Laboratories Ltd. Sponsored ADR D C D RSG Republic Services, Inc. D C D SCI Service Corporation International D C D SJM J.M. Smucker Company D C D TSN Tyson Foods, Inc. Class A D D D TTWO Take-Two Interactive Software, Inc. D B D

Upgraded: Very Weak to Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade Z Zillow Group, Inc. Class C F C D

Downgraded: Weak to Very Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AMH American Homes 4 Rent Class A F C F BEKE KE Holdings, Inc. Sponsored ADR Class A F D F MKC McCormick & Company, Incorporated F C F

To stay on top of my latest stock ratings, plug your holdings into Stock Grader, my proprietary stock screening tool. But, you must be a subscriber to one of my premium services.

Story Continues

To learn more about my premium service, Growth Investor, and get my latest picks, go here. Or, if you are a member of one of my premium services, you can go here to get started.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Sincerely,An image of a cursive signature in black text.

Louis Navellier

Editor, Market 360

The post ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks appeared first on InvestorPlace.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 112 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.

This Week’s Ratings Changes:

Upgraded: Strong to Very Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AMAT Applied Materials, Inc. A B A APA APA Corporation A C A BWXT BWX Technologies, Inc. A B A CACI CACI International Inc Class A A C A CMI Cummins Inc. A C A DINO HF Sinclair Corporation A C A EME EMCOR Group, Inc. A B A GOOG Alphabet Inc. Class C A B A HTHT H World Group Limited Sponsored ADR A B A JBL Jabil Inc. A B A LMT Lockheed Martin Corporation A B A MPC Marathon Petroleum Corporation A B A MTSI MACOM Technology Solutions Holdings, Inc. A B A NVMI Nova Ltd. A C A NVT nVent Electric plc A B A VIK Viking Holdings Ltd A B A WDS Woodside Energy Group Ltd Sponsored ADR A B A XOM Exxon Mobil Corporation A C A

Downgraded: Very Strong to Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AGI Alamos Gold Inc. B A B APH Amphenol Corporation Class A A B B BIP Brookfield Infrastructure Partners L.P. A B B CLH Clean Harbors, Inc. A C B CNP CenterPoint Energy, Inc. A C B COR Cencora, Inc. A C B DG Dollar General Corporation A B B DTM DT Midstream, Inc. A C B FNV Franco-Nevada Corporation B B B GFI Gold Fields Limited Sponsored ADR A B B IX ORIX Corporation Sponsored ADR A B B MCK McKesson Corporation A C B NTR Nutrien Ltd. A C B UTHR United Therapeutics Corporation A C B VTR Ventas, Inc. A B B

Upgraded: Neutral to Strong

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade COP ConocoPhillips B D B CQP Cheniere Energy Partners, L.P. B B B CTRA Coterra Energy Inc. B C B DAL Delta Air Lines, Inc. B C B GMED Globus Medical Inc Class A B B B HLT Hilton Worldwide Holdings Inc. B D B IHG InterContinental Hotels Group PLC Sponsored ADR B C B LH Labcorp Holdings Inc. B C B LNG Cheniere Energy, Inc. B B B LVS Las Vegas Sands Corp. B B B MAR Marriott International, Inc. Class A B D B MRNA Moderna, Inc. B C B MS Morgan Stanley B B B NIO NIO Inc. Sponsored ADR Class A B B B NUE Nucor Corporation B C B PSTG Everpure, Inc. Class A C B B RDDT Reddit, Inc. Class A C B B TPL Texas Pacific Land Corporation B C B

Downgraded: Strong to Neutral

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AEE Ameren Corporation B C C AGNC AGNC Investment Corp. C B C ALNY Alnylam Pharmaceuticals, Inc C C C ARGX argenx SE Sponsored ADR C C C BUD Anheuser-Busch InBev SA/NV Sponsored ADR C C C COST Costco Wholesale Corporation C C C CVS CVS Health Corporation C B C ELS Equity LifeStyle Properties, Inc. C C C IRM Iron Mountain, Inc. C C C JBS JBS N.V. Class A C C C LLY Eli Lilly and Company C B C LYV Live Nation Entertainment, Inc. B D C MLM Martin Marietta Materials, Inc. B D C MSI Motorola Solutions, Inc. C C C NLY Annaly Capital Management, Inc. C B C NWG NatWest Group Plc Sponsored ADR C B C PM Philip Morris International Inc. B C C REG Regency Centers Corporation C B C RIVN Rivian Automotive, Inc. Class A B D C TKO TKO Group Holdings, Inc. Class A B D C TLN Talen Energy Corp B D C UL Unilever PLC Sponsored ADR C C C WEC WEC Energy Group Inc B C C

Upgraded: Weak to Neutral

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AEG Aegon Ltd. Sponsored ADR D C C AIZ Assurant, Inc. C C C ARM ARM Holdings PLC Sponsored ADR C C C COF Capital One Financial Corp D C C DECK Deckers Outdoor Corporation D B C DXCM DexCom, Inc. D B C ENTG Entegris, Inc. C C C FTV Fortive Corp. D C C IR Ingersoll Rand Inc. D C C ISRG Intuitive Surgical, Inc. D C C NXPI NXP Semiconductors NV D C C TFC Truist Financial Corporation C C C TU TELUS Corporation C D C WSM Williams-Sonoma, Inc. C C C

Downgraded: Neutral to Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade ADSK Autodesk, Inc. D B D AMT American Tower Corporation D C D AZO AutoZone, Inc. D D D BDX Becton, Dickinson and Company D C D BJ BJ's Wholesale Club Holdings, Inc. D C D CTAS Cintas Corporation D C D EXR Extra Space Storage Inc. D C D FMS Fresenius Medical Care AG Sponsored ADR D B D HDB HDFC Bank Limited Sponsored ADR F C D LOW Lowe's Companies, Inc. D D D MSFT Microsoft Corporation D B D PSA Public Storage D C D PTC PTC Inc. D B D RBLX Roblox Corp. Class A D C D RDY Dr. Reddy's Laboratories Ltd. Sponsored ADR D C D RSG Republic Services, Inc. D C D SCI Service Corporation International D C D SJM J.M. Smucker Company D C D TSN Tyson Foods, Inc. Class A D D D TTWO Take-Two Interactive Software, Inc. D B D

Upgraded: Very Weak to Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade Z Zillow Group, Inc. Class C F C D

Downgraded: Weak to Very Weak

Symbol Company Name Quantitative Grade Fundamental Grade Total Grade AMH American Homes 4 Rent Class A F C F BEKE KE Holdings, Inc. Sponsored ADR Class A F D F MKC McCormick & Company, Incorporated F C F

To stay on top of my latest stock ratings, plug your holdings into Stock Grader, my proprietary stock screening tool. But, you must be a subscriber to one of my premium services.

Story Continues

To learn more about my premium service, Growth Investor, and get my latest picks, go here. Or, if you are a member of one of my premium services, you can go here to get started.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Sincerely,An image of a cursive signature in black text.

Louis Navellier

Editor, Market 360

The post Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks appeared first on InvestorPlace.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Fresenius Medical Care AG (NYSE:FMS) is among the best German stocks to buy according to analysts. On February 24, Fresenius Medical Care AG (NYSE:FMS) released its Q4 2025 results. The company posted EPS of €1.14, compared to €0.23 in the same quarter in 2024. It delivered revenue of €5.1 billion, flat from the year-ago quarter.Fresenius Medical Care AG (FMS) Looks to Improve Profitability After Smashing Q4 Expectations

yezry/Shutterstock.com

The management said the earnings numbers met internal targets, attributing this to efforts over the past three years that have focused on building a more resilient company. The management added that the achievements reflect a disciplined approach to operational and financial decisions.

Looking ahead, Fresenius Medical Care AG’s management spoke about further improving profitability, investing in the future, and overcoming regulatory headwinds. With this focus, the company is expecting 3% – 7% CAGR for operating income between 2025 and 2028. Additionally, the company aims to increase returns for shareholders.

In other news, Fresenius Medical Care AG has proposed a dividend of €1.49 per share based on 2025 earnings. The company said the proposed dividend is a 3% increase and represents a payout of about 33%. The company aims to maintain a stable dividend program at a payout ratio of 30% – 40%.

German healthcare company Fresenius Medical Care AG (NYSE:FMS) operates a network of 3,601 kidney dialysis clinics. These dialysis centers serve around 292,000 patients around the world. The company also provides dialysis machines.

While we acknowledge the potential of FMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung:

Dieser Text bewirbt einen kostenlosen Aktienanalysebericht von Zacks Investment Research. Es wird speziell ein Bericht mit "7 Besten Aktien für die nächsten 30 Tage" hervorgehoben, mit Fresenius Medical Care AG & Co. KGaA (FMS) als einer der Empfehlungen. Die Quelle des Berichts ist die Website Zacks Investment Research (zacks.com).

Would you like me to adjust the summary or translation in any way, or perhaps translate a different piece of text?

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here’s a 600-word summary of the provided text, followed by a German translation:

Summary (600 words)

Fresenius Medical Care AG & Co. FMS reported a strong fourth quarter and full-year performance in 2025, exceeding analyst expectations and demonstrating the positive impact of its strategic initiatives. The company’s adjusted earnings per share (EPS) surged by 59% year-over-year, reaching 83 cents for the fourth quarter and $2.47 for the full year.

Revenue growth, while initially down 0.3% year-over-year, was bolstered by significant currency adjustments (constant currency – cc). Overall, revenues hit $5.88 billion for the quarter and $22.76 billion for the year, representing growth of 1.5% and 5.4% respectively (cc). Organic revenue growth was also a solid 8% across both periods.

Several factors influenced the company’s performance. The “FME25+” transformation program, a key strategic initiative, generated substantial savings, totaling EUR 238 million in 2025 and EUR 804 million cumulatively over the past three years. FMS plans to expand this program, aiming for an additional EUR 1.2 billion in savings by 2027. However, revenue was negatively impacted by divestitures related to the portfolio optimization plan, specifically 70 basis points in the fourth quarter and 130 basis points for the full year.

Segmentally, the “Care Delivery” segment saw a 1.8% year-over-year decline but exhibited strong growth at cc (5.7%) and organically (7%). U.S. market revenues decreased 0.9% reported but increased 7.7% at cc and 8% organically, largely due to favorable reimbursement regulations (TDAPA), favorable payer mix, and reduced implicit price concessions. U.S. same-market treatment growth declined 0.2% year-over-year. International sales experienced a 6.1% decline reported and 4.4% at cc but increased 3% organically, again influenced by divestitures and unfavorable exchange rates.

The “Care Enablement” segment faced a significant 8.8% year-over-year decline in revenues and 3.2% at cc and organically, primarily due to unfavorable currency and volume pressures in China. Positive pricing momentum partially offset these negative impacts. The “Value-Based Care” segment reported a substantial 31.6% year-over-year revenue surge at both cc (42.4%) and organically, driven by increased member months (contract expansion) and, to some extent, unfavorable exchange rate effects.

Looking ahead, FMS anticipates flat revenue growth for 2026, coupled with mid-single-digit percentage point decline or growth in operating income. The company’s long-term strategy includes a CAGR of 3-7% for operating income between 2028 and 2030, alongside specific growth targets for its key segments. The launch of the high-volume hemodiafiltration (HVHDF) 5008X CARE system is expected to contribute to top-line growth.

German Translation (approx. 600 words)

Zusammenfassung der Ergebnisse von Fresenius Medical Care AG & Co. FMS für 2025

Fresenius Medical Care AG & Co. FMS hat im vierten Quartal und im Gesamtjahr 2025 starke Ergebnisse erzielt, die die Erwartungen der Analysten übertroffen und das Ergebnis strategischer Initiativen verdeutlichen. Der bereinigte Gewinn pro Aktie (EPS) stieg im Jahresvergleich um 59 %, erreichte 83 Cent für das vierte Quartal und 2,47 Dollar für das Gesamtjahr.

Der Umsatz, zunächst um 0,3 % im Jahresvergleich gesunken, profitierte von erheblichen Währungseffekten (konstante Währung – cc). Insgesamt wurden 5,88 Milliarden Dollar im Quartal und 22,76 Milliarden Dollar im Gesamtjahr erzielt, was einem Wachstum von 1,5 % bzw. 5,4 % entspricht. Auch der organische Umsatzwachstum lag bei soliden 8 % in beiden Perioden.

Mehrere Faktoren beeinflussten die Unternehmensleistung. Das “FME25+” Transformationsprogramm, eine wichtige strategische Initiative, generierte erhebliche Einsparungen, die 2025 238 Millionen Euro und kumulativ 804 Millionen Euro über die letzten drei Jahre betrugen. FMS plant, dieses Programm weiter auszubauen und zusätzliche Einsparungen von 1,2 Milliarden Euro bis 2027 zu erzielen. Allerdings wurde der Umsatz durch Divestitionen im Zusammenhang mit dem Portfolio-Optimierungsprogramm negativ beeinflusst, insbesondere um 70 Basispunkte im vierten Quartal und 130 Basispunkte für das Gesamtjahr.

Segmentbezogen lag der Umsatz im Segment “Care Delivery” um 1,8 % im Jahresvergleich niedriger, zeigte aber starke Wachstumsraten bei cc (5,7 %) und organisch (7 %). Die Umsätze in den US-Märkten sanken um 0,9 % im Berichtszeitraum, stiegen aber bei cc um 7,7 % und 8 % organisch, hauptsächlich aufgrund günstigerer Vergütungsregelungen (TDAPA), einer günstigen Verbeitragsstruktur und geringeren impliziten Preisnachlässen. Das Behandlungswachstum im US-Markt sank um 0,2 % im Jahresvergleich. Die internationalen Umsätze sanken um 6,1 % im Berichtszeitraum und 4,4 % bei cc, stiegen aber organisch um 3 %, beeinflusst erneut durch Divestitionen und ungünstige Wechselkurse.

Das Segment “Care Enablement” erlebte einen erheblichen Rückgang von 8,8 % im Jahresvergleich für den Umsatz und 3,2 % bei cc und organisch, hauptsächlich aufgrund ungünstiger Währung und Volumendrucks in China. Positiver Preisdruck teilte diese negativen Auswirkungen teilweise aus. Das Segment “Value-Based Care” meldete einen erheblichen Anstieg des Umsatzes von 31,6 % im Jahresvergleich bei cc (42,4 %) und organisch, getrieben durch erhöhte Mitgliedermonate (Vertragsausweitung) und teilweise ungünstige Wechselkurseffekte.

Mit Blick auf die Zukunft erwartet FMS für 2026 flächenübergreifendes Umsatzwachstum, gepaart mit einem Rückgang oder Wachstum des operativen Einkommens im mittleren einstelligen Prozentbereich. Das Unternehmen plant mit einer CAGR von 3–7 % für das operative Einkommen zwischen 2028 und 2030 und legt spezifische Wachstumsziele für seine wichtigsten Segmente fest. Der Start des High-Volume-Hemodiafiltration (HVHDF) 5008X CARE Systems wird voraussichtlich zu Umsatzsteigerungen beitragen.